Su Joa Ahn1, Jeong Min Lee2, Dong Ho Lee1, Sang Min Lee1, Jung-Hwan Yoon3, Yoon Jun Kim3, Jeong-Hoon Lee3, Su Jong Yu3, Joon Koo Han4. 1. Department of Radiology, Seoul National University Hospital, Seoul, South Korea. 2. Department of Radiology, Seoul National University Hospital, Seoul, South Korea; Institute of Radiation Medicine, Department of Internal, Seoul National University Hospital, Seoul, South Korea. Electronic address: jmsh@snu.ac.kr. 3. Department of internal medicine, Seoul National University Hospital, Seoul, South Korea. 4. Department of Radiology, Seoul National University Hospital, Seoul, South Korea; Institute of Radiation Medicine, Department of Internal, Seoul National University Hospital, Seoul, South Korea.
Abstract
BACKGROUND & AIMS: Although ultrasonography (US) guided radiofrequency ablation (RFA) is a commonly used treatment option for early hepatocellular carcinoma (HCC), inconspicuous tumors on US limits its feasibility. Thus, we prospectively determined whether real-time US-CT/MR fusion imaging can improve the technical feasibility of RFA compared with B-mode US, and help predict local tumor progression after RFA in patients with HCC. METHODS: A total of 216 patients with 243 HCCs ⩽5cm referred for RFA were prospectively enrolled. Prior to RFA, the operators scored the visibility of tumors, and technical feasibility on a 4-point scale at both B-mode US and fusion imaging. RFA was performed with a switching monopolar system using a separable cluster electrode under fusion imaging guidance. Technique effectiveness, local tumor progression and intrahepatic remote recurrences were evaluated. RESULTS: Tumor visibility and technical feasibility were significantly improved with fusion imaging compared with B-mode US (p<0.001). Under fusion imaging guidance, the technique effectiveness of RFA for invisible tumors on B-mode US was similar to those for visible tumors (96.1% vs. 97.6%, p=0.295). Estimated cumulative incidence of local tumor progression at 24months was 4.7%, and previous treatment for other hepatic tumors (p=0.01), higher expected number of electrode insertions needed and lower technical feasibility scores (p<0.01) on fusion imaging were significant negative predictive factors for local tumor progression. CONCLUSION: Real-time fusion imaging guidance significantly improved the tumor visibility and technical feasibility of RFA in patients with HCCs compared with B-mode US, and low feasibility scores on fusion imaging was a significant negative predictive factor for local tumor progression. LAY SUMMARY: US/CT-MR fusion imaging guidance improved the tumor visibility and technical feasibility of RFA in patients with HCCs. In addition, fusion imaging guided RFA using multiple electrodes demonstrated a high technique effectiveness rate and a low local tumor progression rate during mid-term follow-up. Clinical trial number: ClinicalTrials.gov number, NCT02687113.
BACKGROUND & AIMS: Although ultrasonography (US) guided radiofrequency ablation (RFA) is a commonly used treatment option for early hepatocellular carcinoma (HCC), inconspicuous tumors on US limits its feasibility. Thus, we prospectively determined whether real-time US-CT/MR fusion imaging can improve the technical feasibility of RFA compared with B-mode US, and help predict local tumor progression after RFA in patients with HCC. METHODS: A total of 216 patients with 243 HCCs ⩽5cm referred for RFA were prospectively enrolled. Prior to RFA, the operators scored the visibility of tumors, and technical feasibility on a 4-point scale at both B-mode US and fusion imaging. RFA was performed with a switching monopolar system using a separable cluster electrode under fusion imaging guidance. Technique effectiveness, local tumor progression and intrahepatic remote recurrences were evaluated. RESULTS:Tumor visibility and technical feasibility were significantly improved with fusion imaging compared with B-mode US (p<0.001). Under fusion imaging guidance, the technique effectiveness of RFA for invisible tumors on B-mode US was similar to those for visible tumors (96.1% vs. 97.6%, p=0.295). Estimated cumulative incidence of local tumor progression at 24months was 4.7%, and previous treatment for other hepatic tumors (p=0.01), higher expected number of electrode insertions needed and lower technical feasibility scores (p<0.01) on fusion imaging were significant negative predictive factors for local tumor progression. CONCLUSION: Real-time fusion imaging guidance significantly improved the tumor visibility and technical feasibility of RFA in patients with HCCs compared with B-mode US, and low feasibility scores on fusion imaging was a significant negative predictive factor for local tumor progression. LAY SUMMARY: US/CT-MR fusion imaging guidance improved the tumor visibility and technical feasibility of RFA in patients with HCCs. In addition, fusion imaging guided RFA using multiple electrodes demonstrated a high technique effectiveness rate and a low local tumor progression rate during mid-term follow-up. Clinical trial number: ClinicalTrials.gov number, NCT02687113.
Authors: Marco Calandri; Valeria Ruggeri; Patrizia Carucci; Stefano Mirabella; Andrea Veltri; Paolo Fonio; Carlo Gazzera Journal: Radiol Med Date: 2019-07-03 Impact factor: 3.469
Authors: Robert M Pohlman; Michael R Turney; Po-Hung Wu; Christopher L Brace; Timothy J Ziemlewicz; Tomy Varghese Journal: Med Phys Date: 2019-05-06 Impact factor: 4.071
Authors: Dong Ho Lee; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han Journal: Eur Radiol Date: 2019-01-14 Impact factor: 5.315
Authors: Mohamed A Abbass; Allison-Joy Garbo; Neeraja Mahalingam; Jakob K Killin; T Douglas Mast Journal: IEEE Trans Ultrason Ferroelectr Freq Control Date: 2018-06-14 Impact factor: 2.725
Authors: Sae-Jin Park; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Jin Kang; Jeong Hee Yoon; Dong Ho Lee; Se Hyung Kim; Jae Young Lee; Jeong Min Lee Journal: Liver Cancer Date: 2020-12-08 Impact factor: 11.740
Authors: Robert M Pohlman; James L Hinshaw; Timothy J Ziemlewicz; Meghan G Lubner; Shane A Wells; Fred T Lee; Marci L Alexander; Kelly L Wergin; Tomy Varghese Journal: Ultrasound Med Biol Date: 2021-05-16 Impact factor: 3.694